GenSight appoints new COO
This article was originally published in Scrip
Paris, France-based GenSight Biologics, which develops gene-based therapies to preserve or restore vision in people with degenerative retinal and inherited ophthalmologic diseases, has named Dr Jean-Philippe Combal chief operating officer. Dr Combal will lead the company's operational activities and the development of its products. Prior to joining GenSight, he was leading development of early stage dermatological products – up to Phase IIb – at Galderma International.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.